Navigation Links
Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
Date:10/23/2007

ding the University of Pittsburgh and the University of California, San Diego. Jennerex is planning to initiate a Phase 2a for squamous cell head and neck cancers in early 2008. The company also plans to conduct clinical trials for patients with lung cancer and melanoma.

"The broad clinical efficacy reported by these investigators strongly validates this first-in-class product, JX-594, and its novel mechanism-of-action. These exciting clinical results mirror closely what has been reported in preclinical studies," said David H. Kirn, M.D., CEO and President of Jennerex. "We are extremely grateful for the support of our clinical collaborators, as well as for the sponsorship of our partners for South Korea at Green Cross Corporation."

"We are very pleased to be collaborating with Jennerex for the development of this kind of exciting new drug, JX-594, in Korea," said B.G. Rhee, Ph.D., executive vice president of Green Cross. Jennerex has an exclusive partnership with Green Cross for the South Korean market only.

About JX-594

Jennerex's lead product candidate, JX-594, is a genetically-engineered vaccinia virus strain that is uniquely suited to treat cancers. It is designed to destroy both injected and non-injected metastatic tumors.

About Jennerex

Jennerex Biotherapeutics is a clinical stage biotherapeutics company working to create, develop and commercialize first-in-class cancer products. The company's products are engineered viruses that have been modified to be safe and effective against various forms of cancer. Jennerex products seek to kill cancer by targeting, attacking and eradicating cancer cells. The company's lead product candidate, JX-594, demonstrated clear anti-cancer effects in patients in a Phase 1 / 2 clinical trial. A Phase 2a clinical trial for liver cancer is currently being initiated. A Phase 2 trial for JX-594 in squamous cell head and neck cancer is expected to begin in the first quarter of 2008. JX-594 is the fi
'/>"/>

SOURCE Jennerex Biotherapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. Pharmexa A/S (DK) - Pharmexa presents data from influenza program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... VIEW, Calif., Feb. 10, 2011 ZONARE Medical Systems, ... z.one Ultrasound System to Woodlands Church of Plover, WI, ... the past year, ZONARE has provided six systems to ... and medical missions. Woodlands Church performs annual ...
... AlphaDetail, a leader in global primary market research for ... in revenue in 2010, exceeding $18.5M in annual revenue ... "Our clients have delivered a loud and clear ... get at the heart of their strategic information needs," ...
Cached Medicine Technology:ZONARE Provides z.one Ultrasound System for Medical Missions to Guatemala 2ZONARE Provides z.one Ultrasound System for Medical Missions to Guatemala 3AlphaDetail Revenue Soars 30% in 2010 2
(Date:7/9/2014)... Wakulich was told she had an aneurysm, she figured an ... , "I was devastated," said Wakulich, who is 56 years ... was a serious diagnosis. Then I met Dr. Bernard Bendok ... less invasive procedure. It was something I didn,t even know ... multi-center U.S. clinical trial to evaluate the safety and effectiveness ...
(Date:7/9/2014)... support cells and immune cells and the role ... development of diseases could open new therapeutic avenues ... conclusion of a review article by scientists from VIB ... . , Prof. Peter Carmeliet: "Consider the review article ... cells has been examined in minute detail for decades ...
(Date:7/9/2014)... Researchers from The Miriam Hospital have found that ... are also depressed have difficulty sticking to a ... true for women, and screening and brief treatment ... treatment. The study and its findings are published ... , Chronic obstructive pulmonary disease is a common ...
(Date:7/9/2014)... Researchers from Montefiore Medical Center and the ... University will present new findings at the Alzheimer,s Association ... 17 in Copenhagen, Denmark. Data from the four abstracts ... cognitive normality to mild cognitive impairment and dementia. The ... , established in 1980 to examine healthy brain aging ...
(Date:7/9/2014)... Diseases (NIAID), part of the National Institutes of ... CRS3123, an investigational oral antibiotic intended to treat ... infection. CRS3123 (previously known as REP3123) is a ... sparing normal intestinal bacteria. , The Phase I ... and women ages 18 to 45 in a ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... Nfocus Neuromedical, Inc.,today announced that the company ... and Delivery System. The CardioVasc(TM),Stent-Graft is a minimally ... Lesions (SVGs) from a previous coronary bypass, Vessel,Perforations ... Nfocus to,begin marketing the CardioVasc(TM) Stent-Graft in the ...
... Division becomes newest reseller ... xTag wireless microphone, MAYNARD, Mass., Feb. 12 ... for enhancing collaboration, today announced,that the Dictaphone Healthcare ... xTag Wireless Microphone alongside its Dragon(R),NaturallySpeaking(R) Medical speech ...
... high-end ,infotainment, systems manufacturer to manage global ... manufacturing operations with Visiprise Manufacturing, ... leader in,integrated manufacturing execution (MES) solutions today ... Harman,International, has selected Visiprise Manufacturing as their ...
... TeamStaff, Inc.,(Nasdaq: TSTF ) a national ... today that it is changing the name ... Inc., to TeamStaff,Government Solutions (dba TeamStaff GS)., ... provides medical, office,administration and logistics professionals through ...
... Mich., Feb. 12 Affiliated Computer,Services, Inc. (ACS) ... Healthcare Solutions -- has earned four no. 1 ... Awards, issued by KLAS Enterprises, LLC., The ... Implementation Principal,Financial Implementation Supportive, Staff Augmentation, and Other,Implementation ...
... AMN Healthcare Services,Inc. (NYSE: AHS ), ... Hala Moddelmog, President and Chief Executive Officer,of Susan ... company,s Board of,Directors., "Hala brings valuable experience ... in the global breast cancer movement and,previously, as ...
Cached Medicine News:Health News:Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System 2Health News:Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance 2Health News:Revolabs xTag(TM) Wireless Microphone Now Offered as a Total Solution With Dragon(R) NaturallySpeaking(R) Medical Software from Nuance 3Health News:Harman/Becker Automotive Systems Completes Initial Deployments of Visiprise Integrated Manufacturing Execution 2Health News:Harman/Becker Automotive Systems Completes Initial Deployments of Visiprise Integrated Manufacturing Execution 3Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:ACS is 'Best in KLAS' for Healthcare Consulting Services 2Health News:AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors 2Health News:AMN Healthcare Appoints Hala Moddelmog to Its Board of Directors 3
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
Medicine Products: